Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Bryan Davies
University of Texas, Austin, Department: Biology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Anexigen Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The Covered Individual is co-founder and will serve as Consultant and Scientific Advisory Board Member for Anexigen Therapeutics. The Covered Individual holds equity interest in Anexigen Therapeutics, and has received travel reimbursement for work with the company. The Covered Individual will receive monetary payment for consulting work with Anexigen Therapeutics. The Covered Individual is co-inventor of technology (Assigned to Board of Regents, UT System) that is relevant to the business interests of Anexigen Therapeutics. The business interests of Anexigen Therapeutics are related to this research.
A High-Throughput Molecular Platform for Antimicrobial Discovery and Study
Project Narrative. 700,000 people die annually from antibiotic-resistant bacterial infections. This number is projected to increase more than 10-fold over the next three decades, unless new treat options are found. Our objective in this proposal is to develop and implement a new molecular approach to drug screening for an in-depth study of peptide chemistry with antimicrobial activity against antibiotic-resistant, Gram-negative bacterial pathogens.�
Filed on April 25, 2018.
Tell us what you know about Bryan Davies's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Bryan Davies filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Bryan Davies | University of Texas, Austin | Conflict of Interest | Anexigen Therapeutics | $10,000 - $19,999 |
| Bryan Davies | University of Texas, Austin | Conflict of Interest | Anexigen Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.